60 DEGREES PHARMACEUTICALS, INC.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
SXTP$0.52-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Balance Sheets
| March 31, 2025 | December 31, | |
|---|---|---|
| (Unaudited) | 2024 | |
| ASSETS: | ||
| Current Assets: | ||
| Cash and Cash Equivalents | $3,451,500 | $1,659,353 |
| Accounts Receivable | 488,243 | 486,748 |
| Prepaid and Other Assets | 937,250 | 1,068,940 |
| Short-Term Investments | - | 1,728,472 |
| Inventory (Note 3) | 773,238 | 442,764 |
| Total Current Assets | 5,650,231 | 5,386,277 |
| Property and Equipment, net (Note 4) | 155,792 | 149,808 |
| Other Assets: | ||
| Long-Term Prepaid Expense | 22,059 | 66,176 |
| Intangible Assets, net (Note 5) | 149,785 | 157,084 |
| Total Other Assets | 171,844 | 223,260 |
| Total Assets | $5,977,867 | $5,759,345 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY: | ||
| Current Liabilities: | ||
| Accounts Payable and Accrued Expenses | $1,157,979 | $1,007,618 |
| SBA EIDL (including accrued interest) (Note 7) | 8,772 | 8,772 |
| Derivative Liabilities (Note 8) | 635,725 | 640,830 |
| Total Current Liabilities | 1,802,476 | 1,657,220 |
| Long-Term Liabilities: | ||
| SBA EIDL (including accrued interest) (Note 7) | 146,502 | 147,119 |
| Total Long-Term Liabilities | 146,502 | 147,119 |
| Total Liabilities | 1,948,978 | 1,804,339 |
| Commitments and Contingencies (Note 11) | ||
| SHAREHOLDERS’ EQUITY: | ||
| Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 76,480 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively (Note 6) | 9,567,439 | 9,567,439 |
| Common Stock, $0.0001 par value, 150,000,000 shares authorized; 1,472,891 and 566,908 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively(1) (Note 6) | 147 | 57 |
| Additional Paid-in Capital(1) | 36,821,588 | 34,860,590 |
| Accumulated Other Comprehensive Income | 125,567 | 135,471 |
| Accumulated Deficit | (42,404,506) | (40,527,957) |
| 60P Shareholders’ Equity: | 4,110,235 | 4,035,600 |
| Noncontrolling Interest | (81,346) | (80,594) |
| Total Shareholders’ Equity | 4,028,889 | 3,955,006 |
| Total Liabilities and Shareholders’ Equity | $5,977,867 | $5,759,345 |
| (1) | Prior periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024 and the 1:5 reverse stock split on February 24, 2025. |
*The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.